ARTICLE | Clinical News
Ridinilazole: Phase II data
December 7, 2015 8:00 AM UTC
Top-line data from the double-blind, North American Phase II CoDIFy trial in 100 patients with CDI showed that twice-daily 200 mg oral ridinilazole for 10 day met the primary endpoint of non-inferiori...